Tonix Pharmaceuticals Holding Corp. (TNXP)

3.40
0.02 0.59
NASDAQ : Health Technology
Prev Close 3.38
Open 3.30
Day Low/High 3.30 / 3.43
52 Wk Low/High 2.85 / 9.40
Volume 18.10K
Avg Volume 71.00K
Exchange NASDAQ
Shares Outstanding 7.80M
Market Cap 25.82M
EPS -15.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Tonix Pharmaceuticals Receives Notice Of Allowance For New U.S. Patent For The Active Ingredient In Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)

Tonix Pharmaceuticals Receives Notice Of Allowance For New U.S. Patent For The Active Ingredient In Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)

Patent Will Provide Intellectual Property Protection until 2030 for Use of Cyclobenzaprine in the Treatment of Posttraumatic Stress Disorder (PTSD)

Tonix Pharmaceuticals Completes Positive Pre-IND Meeting With FDA For TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) As A Clinical Candidate For Agitation In Alzheimer's Disease

Tonix Pharmaceuticals Completes Positive Pre-IND Meeting With FDA For TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) As A Clinical Candidate For Agitation In Alzheimer's Disease

FDA Official Minutes Support Tonix's Plan to File an IND in First Quarter 2018 for a Phase 2 Study

Mirati Skyrockets On Positive Data - Biotech Movers

Mirati Skyrockets On Positive Data - Biotech Movers

The San Diego firm is scheduled to present positive preliminary data for two clinical studies of sitravatinib in non-small cell lung cancer at a symposium in Chicago on Friday.

Tonix Pharmaceuticals Receives European Patent For The Active Ingredient In Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)

Tonix Pharmaceuticals Receives European Patent For The Active Ingredient In Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)

Patent Will Provide Intellectual Property Protection until 2030 for Use of Cyclobenzaprine in the Treatment of Posttraumatic Stress Disorder (PTSD)

Tonix Pharmaceuticals To Present Additional Phase 2 Clinical Results And Design Of Ongoing Phase 3 Trial In Military-Related PTSD At The 2017 Military Health System Research Symposium

Tonix Pharmaceuticals To Present Additional Phase 2 Clinical Results And Design Of Ongoing Phase 3 Trial In Military-Related PTSD At The 2017 Military Health System Research Symposium

Retrospective Analyses from Phase 2 Study of US FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) in PTSD will be Highlighted

Tonix Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides Programs Update

Tonix Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides Programs Update

Interim Analysis of Phase 3 HONOR study of Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) in Military-Related PTSD Expected 1H18 and Topline Results Expected 2H18

Tonix Pharmaceuticals Presented Retrospective Analyses Of Treatment Response And Remission To TNX-102 SL In A Phase 2 Military-Related PTSD Study

Highlights of these Important Findings from AtEase Presented in Pipeline Presentation at the 2017 American Society of Clinical Psychopharmacology Annual Meeting

Tonix Pharmaceuticals To Present Additional Clinical Results Of Military-Related PTSD Study At The 2017 American Society Of Clinical Psychopharmacology Annual Meeting

Important Retrospective Analyses from Phase 2 Study of US FDA-Designated Breakthrough Therapy TNX-102 SL in PTSD will be Highlighted

Tonix Pharmaceuticals Presented Analyses Of Potential Moderators Of Treatment Response To U.S. FDA-Designated Breakthrough Therapy For PTSD, TNX-102 SL, In Phase 2 AtEase Study In Military-Related PTSD

Additional Important Findings Presented in Poster Session at the 72nd Annual Scientific Convention of the Society of Biological Psychiatry

Tonix Pharmaceuticals Reports First Quarter 2017 Financial Results And Provides Programs Update

Phase 3 HONOR Study of U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, Fully Funded and Currently Enrolling

Tonix Pharmaceuticals To Present PTSD Clinical Data At The Society Of Biological Psychiatry 72nd Annual Scientific Convention

Additional Results to be Presented from Phase 2 Study of US FDA-Designated Breakthrough Therapy, TNX-102 SL, in PTSD

Tonix Pharmaceuticals Announces Issuance Of U.S. Patent For TNX-102 SL Composition And Formulation: Designed For Transmucosal Absorption And Bedtime Daily Use

TNX-102 SL is an FDA-Designated Breakthrough Therapy for PTSD in Phase 3 Development